Medicine - Xagena

Medicine

News

Drugs

Xapedia

Farmaci

Farmacia

Medicina

Specialità

Hemacord: FDA has approved first cord blood product

Enzyme replacement therapy with Elaprase for Hunter syndrome

Juvisync, first combination drug to treat type 2 diabetes and high cholesterol in one tablet

Selected risk information for Juvisync, a combination of Sitagliptin and Simvastatin

Sitagliptin is comparable to Glipizide in helping patients lower blood sugar

Zytiga for late-stage prostate cancer, FDA approves

TRITON-TIMI 38 trial: Prasugrel versus Clopidogrel in patients with acute coronary syndrome

Nulojix for preventing acute rejection in kidney transplant recipients

Hepatitis C infection: Telaprevir-based regimen acts faster and offers a stronger viral cure than standard treatment

Eylea for the treatment of patients with neovascular age-related macular degeneration

FDA has approved Rituximab to treat Wegener’s granulomatosis and microscopic polyangiitis

Metastatic melanoma: FDA has approved Yervoy

Fluzone influenza vaccine: VAERS reports of febrile seizures in children

Abnormal heart rhythms may be associated with use of Zofran

Major depressive disorder: FDA has approved Viibryd

FDA has approved Erbitux to treat late-stage head and neck cancer

Knee or hip replacement surgery: FDA has approved Xarelto to reduce risk of blood clots

Corifact for treatment of congenital factor XIII deficiency

Lynch syndrome: Acetylsalicylic acid reduces colorectal cancer rates by around 60%

Prasugrel versus Clopidogrel: non-fatal heart attacks occur less often in certain patients, but major bleeding events are more common

MHRA: the balance of risks and benefits of Reboxetine remains favourable

Follicular lymphoma: vaccine increases disease-free survival

FDA: revised dose limitation for Simvastatin when taken with Amiodarone

Saxagliptin added to Insulin significantly improves glycosylated hemoglobin levels in adults with type 2 diabetes compared to placebo added to Insulin

Idebenone improves sight for patients with Leber's hereditary optic neuropathy

Eylea for neovascular age-related macular degeneration in older people: FDA approved

Expression of dystrophin in Duchenne Muscular Dystrophy patients treated with Eteplirsen

Fasudil, a cardiovascular drug may offer new treatment for some difficult types of leukemia

Multiple sclerosis: Teriflunomide significantly reduces relapse rate, disability progression and disease activity

Raltegravir in combination therapy has shown efficacy and tolerability in adults with HIV-1 regardless of gender or race

Boceprevir: indications and usage for the treatment of chronic hepatitis C genotype 1 infection

Voriconazole and Anidulafungin combination therapy versus Voriconazole alone in invasive aspergillosis

FDA has approved Combivent Respimat inhalation spray for the treatment of patients with chronic obstructive pulmonary disease

Genotype 1 hepatitis C: BMS-790052 plus Peginterferon alfa and Ribavirin demonstrated up to 83% sustained virologic response 24 weeks post-treatment

Selumetinib in patients with KRAS-mutant non-small cell lung cancer

Metabolic therapy for autoimmune diseases: N-Acetylglucosamine suppresses multiple sclerosis attacks

Oral contraceptives containing Drospirenone linked to higher risk of venous thromboembolism than oral contraceptives containing Levonorgestrel

Zoledronic acid and risk of kidney failure: new contraindication in patients with osteoporosis

European Commission: Vibativ for treating adults with nosocomial pneumonia, including ventilator-associated pneumonia

Zytiga for treatment of metastatic castration-resistant prostate cancer in patients who have received prior chemotherapy containing Docetaxel

Long-term use of nonaspirin anti-inflammatory drugs linked to renal cell carcinoma

TNF-alpha blockers: warnings about infection with Legionella and Listeria bacteria

Vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation

Rare diseases: Firazyr, a self-administered subcutaneous treatment for acute hereditary angioedema

FDA has approved orphan drug Zactima for advanced medullary thyroid cancer

FDA approves Firazyr to treat acute attacks of hereditary angioedema

Stomach acid-reducing drugs: proton pump inhibitors may be dangerous

Relapsing-remitting multiple sclerosis: Daclizumab HYP reduces annualized relapse rate

FDA: Afinitor approved for progressive neuroendocrine tumors of pancreatic origin

Revlemid: risk of thrombosis and thromboembolism

Diabetes mellitus: use of Pioglitazone for more than one year associated with an increased risk of bladder cancer

Permanent atrial fibrillation: Multaq and increased risk of death and serious cardiovascular adverse events

Systemic lupus erythematosus: EMA has approved Benlysta

Children born to mothers who took Valproate products while pregnant may have impaired cognitive development

Arcapta Neohaler to treat COPD: FDA approved

Restless legs syndrome: FDA has approved Horizant

2011 - The first vaccine to prevent meningococcal disease in children as young as 9 months: FDA has approved Menactra

Gardasil, HPV vaccine, approved to prevent anal cancer in United States

FDA has approved new indication for Tasigna: newly diagnosed patients with Philadelphia chromosome positive chronic phase chronic myeloid leukemia

FDA has approved Pradaxa to prevent stroke in patients with atrial fibrillation

Crizotinib targets chromosomal rearrangements involving the gene ALK in patients with non-small cell lung cancer

European Commission has approved Brilique for the prevention of atherothrombotic events in patients with acute coronary syndromes

Probuphine's implant has demonstrated compelling efficacy in patients suffering from opioid addiction

Hepatic encephalopathy: FDA has approved new use of Xifaxan for patients with liver disease

Dronedarone, a controversial antiarrhythmic agent, provides only modest efficacy and non clear safety benefits

Acute myocardial infarction: a single bolus of Epoetin alfa does not improve left ventricular ejection fraction

STEMI patients undergoing primary PCI - Three-year follow-up for MULTISTRATEGY trial: Tirofiban versus Abciximab

Hormone positive and HER2-positive advanced breast cancer: Tykerb in combination with Femara

Bydureon improves glycemic control more than daily oral Sitagliptin or Pioglitazone and induces more weight loss

Gilenya: FDA has approved first oral drug to reduce multiple sclerosis relapses

Teflaro for the treatment of adults with community acquired bacterial pneumonia and acute bacterial skin and skin structure infections: FDA approved

Abiraterone improves survival in metastatic castration-resistant prostate cancer

Levetiracetam, Topiramate and Vigabatrin may increase risk of suicide

Everolimus, new indication: treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis

NICE does not recommend Ofatumumab as a treatment for refractory chronic lymphocytic leukaemia

NICE recommends Denosumab as a treatment option for certain postmenopausal women who are at increased risk of osteoporotic fractures

Idiopathic thrombocytopenic purpura: NICE does not recommend Eltrombopag

Women with HER2+ breast cancer: Pertuzumab and Trastuzumab combination improves efficacy

Pazopanib, positive results in the treatment of advanced renal cell carcinoma and ovarian cancer

Diabetes mellitus: FDA has restricted access to Avandia

Iniparib improves overall survival in metastatic triple-negative breast carcinoma

Cetuximab does not add significant benefit to the NORDIC FLOX regimen in first-line treatment of metastatic colorectal carcinoma

Advanced neuroendocrine tumors: Afinitor delays tumor progression

Panitumumab fails to add overall survival benefit in recurrent, metastatic head and neck cancer

Pazopanib shows promise in relapsed, refractory urothelial cancer

Pregnancy: maternal use of proton pump inhibitors is linked to increased risk of cardiac birth defects

Newly diagnosed ovarian cancer: Bevacizumab reduces the risk of disease progression during the first year of treatment

Afatinib improves progression-free in lung adenocarcinoma patients whose cancer progressed after treatment with EGFR inhibitors

Triple negative breast cancer: adding Cetuximab to chemotherapy doubles response rate

MLN8237, an investigational drug shows promise against ovarian cancer resistant or refractory to Platinum-based chemotherapy

Advanced non-small cell lung cancer: benefits for some patients adding MetMAb to Erlotinib

Gefitinib does not improve overall survival in patients with advanced NSCLC with EGFR activating mutations

Osteoarthritis of the hip or knee: Glucosamine and Chondroitin do not work

FDA: Actos and potential increased risk of bladder cancer after two years exposure

Drugs for anxiety or insomnia increase mortality risk by 36 percent

Acute coronary syndrome: safety of two intravenous Heparin doses as adjunct to PCI in patients treated with Fondaparinux

Metastatic renal-cell carcinoma: switch to metronomic chemotherapy could offer new treatment option

EINSTEIN DVT trial: Rivaroxaban is an effective and safe treatment for acute symptomatic deep vein thrombosis

ANTIPAF trial: sartans do not reduce the number of AF episodes in patients with paroxysmal atrial fibrillation and without structural heart disease

AVERROES trial: Apixaban reduces risk of stroke and systemic embolism in atrial fibrillation

Pagine successive 1 [2] 3 4 5

Link

Specialità

Patologie

Patologie

© XAGENA 2010 - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati